Janus Henderson Global Life Sciences Fund Class A (JFNAX)
| Fund Assets | 5.54B |
| Expense Ratio | 0.98% |
| Min. Investment | $2,500 |
| Turnover | 30.00% |
| Dividend (ttm) | 3.59 |
| Dividend Yield | 4.51% |
| Dividend Growth | -5.49% |
| Payout Frequency | Annual |
| Ex-Dividend Date | Dec 5, 2025 |
| Previous Close | 75.02 |
| YTD Return | -4.89% |
| 1-Year Return | 15.06% |
| 5-Year Return | 41.82% |
| 52-Week Low | 60.19 |
| 52-Week High | 82.82 |
| Beta (5Y) | n/a |
| Holdings | 103 |
| Inception Date | Jul 6, 2009 |
About JFNAX
Janus Henderson Global Life Sciences Fund Class A is an actively managed mutual fund specializing in the health and life sciences sector. Its principal objective is to achieve long-term capital growth by investing at least 80% of its assets in equities of companies engaged in biotechnology, pharmaceuticals, healthcare services, and medical devices on a global scale. The fund maintains a diversified portfolio, typically holding between 80 and 120 stocks, and includes both large and smaller capitalization firms. It aims to outperform the MSCI World Health Care Index by at least 2% per annum over any five-year period, before fees. The fund is managed by a dedicated team with expertise in both scientific and business aspects of healthcare, seeking to identify companies addressing unmet medical needs or advancing healthcare system efficiency. Up to 20% of assets may be allocated to emerging markets, and derivatives may be used for risk management or additional capital generation. The strategy is designed for investors seeking exposure to innovation and growth opportunities within the global life sciences industry while maintaining a balanced approach to sector allocation.
Performance
JFNAX had a total return of 15.06% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.51%.
Top 10 Holdings
38.92% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 9.26% |
| Johnson & Johnson | JNJ | 6.37% |
| AstraZeneca PLC | AZN | 4.27% |
| AbbVie Inc. | ABBV | 3.39% |
| UnitedHealth Group Incorporated | UNH | 3.03% |
| Novartis AG ADR | NVSN.MX | 2.67% |
| argenx SE | ARGX | 2.65% |
| Roche Holding AG | ROG | 2.43% |
| Praxis Precision Medicines, Inc. | PRAX | 2.43% |
| Abbott Laboratories | ABT | 2.41% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 5, 2025 | $3.59379 | Dec 5, 2025 |
| Dec 6, 2024 | $3.8026 | Dec 6, 2024 |
| Dec 7, 2023 | $2.86828 | Dec 7, 2023 |
| Dec 20, 2022 | $0.04945 | Dec 20, 2022 |
| Dec 20, 2021 | $6.7078 | Dec 20, 2021 |
| Dec 17, 2020 | $5.47231 | Dec 17, 2020 |